Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Annovis Bio announced full enrollment of 850 patients in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease, exceeding original projections across 83 clinical sites. The trial remains on schedule with a 6-month symptomatic data readout expected in Q1 2027 and an 18-month disease-modifying readout targeted for Q1 2028.
Key figures
- Drug Name
- buntanetap
- Phase Of Trial
- Phase 3
- Dosage mg
- 30
- Clinical sites
- 83
- Patients enrolled
- 850
- Symptomatic readout quarter
- Q1 2027
- Disease modifying readout quarter
- Q1 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.